Idiopathic Generalized Epilepsy Syndromes
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Epilepsy, Epilepsy, Idiopathic Generalized. Basic parameters: 4 years — 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Idiopathic Generalized Epilepsy Syndromes: Clinical Features and Long-term Outcomes
Overview
The idiopathic generalized epilepsies (IGEs) have historically included the syndromes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone (GTCA). Recognition of the IGEs is important for clinical care, as it informs diagnosis, prevents unnecessary investigation, allows optimal selection of anti-seizure medications (ASMs), and provides prognostic guidance. According to the new ILAE definition in 2022, the study aims to describe the clinical features, electroencephalographic, imaging findings and long-term prognosis.
Detailed description
the Long-term prognosis include the rate of drug-resistent epilepsy, relapse after drug withdrawn, common comorbidities such as mood disorders, attention deficit hyperactivity disorder (ADHD) and learning disabilities.
Primary outcome measures
- The proportion of drug-resistent epilepsy [Time frame: through study completion, an average of 1 year]
- The proportion of seizure freedom [Time frame: through study completion, an average of 1 year]
Secondary outcome measures (3)
- The proportion of psychiatric comorbidity [Time frame: through study completion, an average of 1 year]
- The proportion of psychosocial outcome [Time frame: through study completion, an average of 1 year]
- The proportion of seizure relapse after antiseizure medication withdrawn [Time frame: through study completion, an average of 1 year]
Eligibility criteria
Inclusion criteria
- Patients are consecutively and prospectively enrolled from epilepsy center, with newly diagnosed epilepsy or established epilepsy.
- Patients have a diagnosis of idiopathic generalized epilepsy (IGE), according to the 2022 diagnostic criteria.
- Comprehensive clinical information is collected, and 24 hour video-electroencephalography is performed.
- Sign the informed consent forms.
Exclusion criteria
- Other epilepsy syndromes are considered during follow-up, such as genetic generalized epilepsy.
- Lost to follow-up
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China — Hangzhou
Identifiers
NCT: NCT06388174 · S2022-0336